Pharmacology

Aripirazole possesses a novel mechanism of action after in comparison the more FDA sanctioned atypical antipsychotics (i.e. clozapine,olanzapine, quetiapine, ziprasidone, and risperidone). Aripiprazole appears to mediate its antipsychotic results primarily by partial agonism at the D2 receptor. Unfair agonism at D2 receptors has been shown to modulate dopaminergic activity inside areas in which dopastat activity can be high or even moo, like a mesolimbic & mesocortical areas of the schizoid brain, severally. Additionally to unfair agonist activity at a D2 receptor, aripirazole is besides a unfair agonist at a Five-HT1A receptor, & prefer a more untypical antipsychotics, aripiprazole displays an antagonist profile at the Five-HT2A receptor. Aripiprazole has moderate affinity for histamine & alpha sympathomimetic receptors, & there are no appreciable affinity for cholinergic muscarinic receptors.

Pharmacokinetics

Aripiprazole displays linear dynamics by having an elimination half-life of about 75 hours. Accordingly, steadily state plasma concentrations come achieved around astir Xiv years. Cmax (maximal plasma concentration) is achieved inside Three-Five hours when viva voce dosing. A bioavailabilty of the unwritten tablets is all about 90%.

Metabolism

Aripiprazole is metabolized per Cytochrome P450 isoenzymes 3A4 and 2D6. Accordingly, coadministration of aripiprazole using medications that can inhibit(e.g. paroxetine, fluoxetine) or cause (e.g. carbamazepine) these metabolic enzymes may increase or even decrease, severally, plasma concentrations of aripiprazole.

Adverse Events

Adverse cases reported in the pack insert for aripiprazole include headache, infection, disgorgement, drowsiness, insomnia, & akathisia. It appears that aripirazole has the moo incidence of EPS (extrapyramidal side effects). A risks of tardive dyskinesia with prolonged aripirazole use is unreadable.

Dosage Forms

Aripirazole is available around 5mg, 10mg, 15mg, 20mg, & 30mg tablets.

Warnings About Medications with Similar Names

The warning has no more out recently because of this drug's title. A '-prazole' ending of this drug title makes this drug healthy such as these are one of a proton pump inhibitors (such as omeprazole, pantoprazole, lansoprazole) which are utilized within dealing with peptic ulcer disease. Nonetheless, aripiprazole & these doses come around an completely different class of doses altogether & confusing them can lead to a few unneeded side results.

Aripiprazole was develeloped by Otsuka Pharmaceutical Co., Ltd and is manufactured by the Bristol Myers Squibb pharmaceutical company (NYSE: BMY).

Aripiprazole was approved per FDA on November 15, 2002.